Send to

Choose Destination
J Natl Compr Canc Netw. 2016 May;14(5 Suppl):672-4.

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Author information

Presented by Rogerio A. Lilenbaum, MD, Yale Cancer Center/Smilow Cancer Hospital, New Haven, Connecticut, and Leora A. Horn, MD, MSc, FRCPC, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.


For appropriate treatment selection, the updated NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) recommend broad molecular profiling for all patients with nonsquamous disease. Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. Most patients whose disease responds will still experience progression, and the type of disease progression drives management. Systemic progression requires switching TKI treatment, whereas patients with oligoprogression and central nervous system progression may have their new lesions treated but continue on their TKI. A new third-generation TKI has been approved and others are currently under development, and new combinations of these drugs with a VEGFR inhibitor offer promise to improve outcomes.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center